Topias Riuttamäki

@TureMasing Är ca 50% klar - riktigt spännande läsning! Otroligt hur mycket av trading vinsterna kom från affärer som idag är olagliga...

Looking forward to the "2029" sequel. 1929 by Andrew Ross Sorkin audible.com/pd/B0DXQH752D?… The greater the heights of our certainty, the harder and longer we fall

@MrCypherpunk @ChristofferDG Återköp är inte tillåtet på Spotlight i dagsläget. @BitcoinTCAB bolagsstämma har precis godkänt ett upplägg som möjliggör frivillig inlösen av aktier på ett "återköp-liknande" sätt. Det förutsätter dock att intresse finns från aktieägare att lösa in under NAV.

@ChristofferDG Återköp av aktien borde vara en självklarhet nu, även om ni behöver sälja en del btc för det

Lets amplify !

@Sanderandersenn Bravo! 👏

H100 has signed an LOI to acquire ~2,450 BTC, increasing total holdings to ~3,500 BTC. This materially strengthens our scale and positions H100 among the larger listed Bitcoin treasury companies in Europe. The transaction is structured as Bitcoin-for-Bitcoin, ensuring alignment with our long-term Bitcoin strategy. It also brings an experienced investment and technology team, further enhancing our capital markets and treasury capabilities. Following the establishment of our Swiss platform, strengthening financial capacity and institutional positioning has been a clear priority. This marks an important step forward, particularly towards institutional capital in the Nordics and Switzerland.

JUST IN: $14 Trillion BlackRock iShares Preferred and Income Securities ETF just disclosed holding #Bitcoin treasury company Strategy's $STRC, $STRF, $STRK, and $STRD shares worth $471 million. That's 3.3% of the total ETF 🔥

@bryan_johnson @chamath @PeterAttiaMD discusses this in his book, would be interesting to hear him opine on the comment.

Definitely do not stop statins, and preventative LDL-cholesterole lowering therapies in general, based on these arguments, as they clearly misrepresent the facts. The AMORIS study only showed that extremely low total cholesterol was negatively associated with the chance of becoming a centenarian (reaching 100 years of age) (observational association; not causal, and low total cholesterol can also reflect underlying illness in older adults). Total cholesterol is different from LDL. Statins specifically lower LDL in the blood by increasing LDL receptor expression in the liver. The points made here perpetuate a common misconception, often propagated by health influencers, which is mixing up the beneficial functions of a molecule (nearly all naturally occurring biological molecules have legitimate functions in cells, tissues, and organs) with the level of these molecules in the blood, abnormally high levels do not mean a particular molecule is doing its job better, for a simple example, think of glucose, it fuels the brain, too much would not cause your brain to function more, the contrary as it causes metabolic disease, diabetes, and even increases cognitive decline risk. Cholesterol, and even LDL, have their legitimate functions, but these functions do not improve when the molecules are abnormally high in the blood. In fact, elevated LDL in the blood is often an outcome of defective liver uptake, frequently due to metabolic disease, and in rarer cases, solely due to genetics (familial hypercholesterolemia). LDL is causally linked to cardiovascular disease, and lowering it reduces heart attack risks in patients with existing plaque. Mendelian randomization studies also show that lifelong exposure to lower LDL levels reduces coronary artery disease risk; a 38.7 mg/dL reduction correlates to over a 55% reduction in coronary artery disease risk. Moreover, loss-of-function mutations in PCSK9 lead to a 28% reduction in LDL and correlate to an 88% reduction in coronary heart disease. The genetic variants with lower cholesterol share a similar mechanism with statin or PCSK9 treatments, in that they mainly lower LDL by increasing liver clearance. The U-shaped relationship between LDL-cholesterol levels and all-cause mortality at a population level is likely driven by reverse rather than actual causation, since many aging and chronic disease drivers, including inflammation, malnutrition, cancer, and liver disease, can all contribute to lowered levels of lipoprotein. Contrary to the observational data, a large meta-analysis showed that more intensive statin regimens and further reductions in LDL cholesterol produced further reductions in heart disease events and death risk. 20% reduction in coronary heart disease death and 10% reduction in all-cause mortality per 1 mmol/L (38.7 mg/dL) LDL-C reduction across trials. With that said, you might want to reconsider statins in the following cases: A severely lowered LDL coupled with partially increased blood glucose can be a sign of cholesterol "overmedication." The same mechanism that leads to increased clearance by liver uptake also works to increase LDL uptake by pancreatic islet cells. Preclinical evidence shows that overmedication to lower blood LDL can lead to disrupted pancreatic islet functions and insulin secretion, and increased blood glucose (In humans, statins are associated with a modest increase in diabetes risk overall; this is not reliably diagnosed by “LDL too low,” and risk is most evident in predisposed individuals). Consider swapping to PCSK9 inhibitors. This is a well-established injectable (once every month or every two weeks) class of biologics (recombinant monoclonal antibodies targeting PCSK9 and preventing its effect in degrading the LDL receptors in the liver). PCSK9 inhibitors have shown added protective effects in lowering cardiovascular disease risk even in patients already on statins. They also have a speculative anti-aging mechanism since circulating PCSK9 has been shown to increase with aging. While they can also plausibly interfere with the pancreatic islets and cause similar disruption seen with statins, there is no evidence yet to date of PCSK9 inhibitors increasing diabetes risk, such as evidence exists for statins (major outcomes trials have not shown a significant increase in new-onset diabetes over ~2–3 years of follow-up). If your HDL is too low, you need to pursue strategies to increase it, including exercise, healthy diets rich in MUFA and Omega-3 fats and fibers, avoiding added sugar and refined carbs, and abstaining (or seriously cutting down) on alcohol. If you are experiencing muscle ache and discomfort with statins, this is also a strong reason to switch. While the more acute form of muscle degeneration is very rare and would have been detected earlier as you began your statin therapy, lower-grade muscle aches are common in statin users. Changing to PCSK9 inhibitors, or other medications like ezetimibe (a cholesterol absorption blocker), can also help. Personally, I am currently on Repatha, a PCSK9 inhibitor, as I replaced statins after noticing they slightly increased my blood glucose.

.@bryan_johnson should I stop my statin?!?!

BTC AB carries out a directed issue of Preference A shares of approx. SEK 7.2 million Full PR: news.cision.com/btc-ab/r/btc-a…

@ilija_batljan Hatten av! Nu har du en perfekt ursäkt att be Aker berätta dig om deras Bitcoin strategi 😎

Public Property Invest, SBB och Aker. Detta kallas win-win-win💪💪💪 $SBB $Publi $AKERASA #finanstwitter #pratapengar #infrastructure publicproperty.no/en/investor-re…

S&P Global Ratings has assigned Strategy Inc a 'B-' Issuer Credit Rating (Outlook Stable) — the first-ever rating of a Bitcoin Treasury Company by a major credit rating agency. strategy.com/press/s-p-glob…

Report from the extraordinary general meeting in BTC AB Full PR: news.cision.com/btc-ab/r/repor…

@steve_btcfo A great business can be a bad investment if bought at the wrong price.

The challenge with good investments — whether entire sectors or individual stocks — is that markets often get carried away when word spreads or it becomes the 'hot new thing.' Irrational exuberance takes hold. The long-term thesis can still be perfectly sound, but when prices are pushed to extreme valuations, a correction is inevitable. There’s nothing wrong with taking profits when markets overheat. The investment itself hasn’t become worse — it’s simply become mis-priced. Investing doesn't mean religious fervor on every occasion. The problem is for those who jump on later in the day, during the irrational exuberance stage. Sometimes if you're not in early, it's best to sit by the sidelines and wait it out. The investment can remain sound, but only at the right price. Let the price come back to you. On the occurrences it doesn't, who cares, hundreds of other sectors and thousands of other stocks to review.

It’s been a tough couple of months for Bitcoin treasury companies. Join myself and @ChristofferDG for an online Q&A session and our latest news on the market and @BitcoinTCAB. At 13:30 CET On 21 October.

@pbcinc @dagensindustri @nicholasp66 @Assaf_Nathan @RyanReeves_ @SimeonResearch_ @sammutgabi What are your thoughts on today's short report regarding their China operations? maiuspartners.substack.com/p/whats-really… @sammutgabi

@annasvahn_ ATH season 🥳

4000 USD

Sweden, the land of numerous preferred shares from struggling real estate firms, is now embracing a bold new horizon with our Bitcoin-backed preference share. Today @BitcoinTCAB introduces plans for a monthly payout, high yield, high collateral preferred share.

Meanwhile, with rate cuts just 2 weeks away, US Core inflation is back above 3% and on the rise. At 3% annual inflation, the US Dollar will lose over 25% of its purchasing power over the next 10 years. It has already lost ~25% since 2020, only compounding inflation.

High mNAV is a double-edged sword: -If persistent, it gives a treasury company leverage to grow Bitcoin per share rapidly. -If it compresses, the downside is substantial — and recovery from deep drawdowns is asymmetric (an 80% drawdown needs +400% to break even). @BitcoinTCAB ’s position: - mNAV of just 1.15, with 3 months to cover mNAV - Very limited downside with NAV acting as a true floor via our redemption clause (we can redeem shares below NAV). - Strategic use of preferred shares delivers Bitcoin yield regardless of mNAV, while compounding capital even at modest premiums. Moving forward, with caution.

@Puttsson2 @steve_btcfo US OTC trades settle directly on NGM during the period when both markets are open at the same time. Outside this period OTC trades settle between themselves and MM’s who will then settle with help of Nordic partner at NGM open.

@steve_btcfo Do you know how it works between the listings? For example if someone buys 100k shares in US, will some bank/MM counter trade in some way in Sweden to ”move” the shares from Sweden to US? Thinking if you can read any from order book what’s going on.

H100 holders & future buyers: now that the OTC + German listings are live, a few things to keep in mind👇 1️⃣ Best market/liquidity is still the H100 ticker on NGM Stockholm. Always use this as your reference. 2️⃣ The US OTC (HOGPF) trades later than Stockholm & follows BTC sentiment after Europe closes. Liquidity is thin - don’t get carried away. 3️⃣ The Frankfurt listing has even less liquidity than OTC. You’re usually trading against the market maker, not another investor. If NGM is higher, don’t expect to “steal” shares at the old price - they won’t fill you. Frankfurt has same close time as NY but still may not be possible to get a fill after 5:30pm CET. ⚠️ Always use limit orders. Even on NGM it’s illiquid, and even more so on OTC/Frankfurt.

Bitcoin treasury fanboy’s dream to see my idols ⁦@ChristofferDG⁩ and ⁦@Sanderandersenn⁩ on stage together in my hometown of Helsinki. 🤩

Today we set up our first debt instrument, denominated in BTC.